Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]raclopride

Angelo Antonini, Johannes Schwarz, Wolfgang H. Oertel, Oliver Pogarell, Klaus L. Leenders

Research output: Contribution to journalArticle

171 Citations (Scopus)

Abstract

We used [11C]raclopride (RACLO) and positron emission tomography (PET) to study longitudinally striatal dopamine D2 receptor binding in nine patients with Parkinson's disease (PD) at an early drug-naive stage and 3-5 years later, when motor fluctuations had appeared in seven of them. Patients were treated with a combination of levodopa and dopamine agonists. Data were compared with 10 healthy controls in the same age range. Initially, patients with PD showed a significant increase of RACLO uptake in the putamen compared with controls (p <0.04). The caudate nucleus revealed values in the normal range. After 3-5 years, RACLO binding was significantly reduced in the putamen (p <0.03) and caudate nucleus (p <0.03) compared with baseline. Values were now in the control range in the putamen and reduced in the caudate nucleus (p <0.05). The clinical score at 'off' had significantly worsened (p <0.0005) compared with the first PET scan. The nine PD patients reported here had already been investigated 3-4 months after therapy began and at that time did not show a reduction of the initially increased RACLO binding capacity (data published previously). These results indicate long-term downregulation of striatal dopamine D2 receptor binding in PD. Receptor changes in the striatum of patients with PD may be induced by chronic dopaminergic therapy or occur independently of treatment, as a result of structural adaptation of the postsynaptic dopaminergic system to the progressive decline of nigrostriatal neurons.

Original languageEnglish
Pages (from-to)33-38
Number of pages6
JournalMovement Disorders
Volume12
Issue number1
DOIs
Publication statusPublished - 1997

Fingerprint

Raclopride
Corpus Striatum
Dopamine D2 Receptors
Positron-Emission Tomography
Parkinson Disease
Caudate Nucleus
Putamen
Dopamine Agonists
Levodopa
Reference Values
Therapeutics
Down-Regulation
Neurons
Pharmaceutical Preparations

Keywords

  • [C]raclopride
  • Dopamine D receptors
  • Parkinson's disease
  • Positron emission tomography

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease : A study with positron emission tomography and [11C]raclopride. / Antonini, Angelo; Schwarz, Johannes; Oertel, Wolfgang H.; Pogarell, Oliver; Leenders, Klaus L.

In: Movement Disorders, Vol. 12, No. 1, 1997, p. 33-38.

Research output: Contribution to journalArticle

Antonini, Angelo ; Schwarz, Johannes ; Oertel, Wolfgang H. ; Pogarell, Oliver ; Leenders, Klaus L. / Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease : A study with positron emission tomography and [11C]raclopride. In: Movement Disorders. 1997 ; Vol. 12, No. 1. pp. 33-38.
@article{28dacb5328164639a2f6a5c2dbcb572b,
title = "Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]raclopride",
abstract = "We used [11C]raclopride (RACLO) and positron emission tomography (PET) to study longitudinally striatal dopamine D2 receptor binding in nine patients with Parkinson's disease (PD) at an early drug-naive stage and 3-5 years later, when motor fluctuations had appeared in seven of them. Patients were treated with a combination of levodopa and dopamine agonists. Data were compared with 10 healthy controls in the same age range. Initially, patients with PD showed a significant increase of RACLO uptake in the putamen compared with controls (p <0.04). The caudate nucleus revealed values in the normal range. After 3-5 years, RACLO binding was significantly reduced in the putamen (p <0.03) and caudate nucleus (p <0.03) compared with baseline. Values were now in the control range in the putamen and reduced in the caudate nucleus (p <0.05). The clinical score at 'off' had significantly worsened (p <0.0005) compared with the first PET scan. The nine PD patients reported here had already been investigated 3-4 months after therapy began and at that time did not show a reduction of the initially increased RACLO binding capacity (data published previously). These results indicate long-term downregulation of striatal dopamine D2 receptor binding in PD. Receptor changes in the striatum of patients with PD may be induced by chronic dopaminergic therapy or occur independently of treatment, as a result of structural adaptation of the postsynaptic dopaminergic system to the progressive decline of nigrostriatal neurons.",
keywords = "[C]raclopride, Dopamine D receptors, Parkinson's disease, Positron emission tomography",
author = "Angelo Antonini and Johannes Schwarz and Oertel, {Wolfgang H.} and Oliver Pogarell and Leenders, {Klaus L.}",
year = "1997",
doi = "10.1002/mds.870120107",
language = "English",
volume = "12",
pages = "33--38",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease

T2 - A study with positron emission tomography and [11C]raclopride

AU - Antonini, Angelo

AU - Schwarz, Johannes

AU - Oertel, Wolfgang H.

AU - Pogarell, Oliver

AU - Leenders, Klaus L.

PY - 1997

Y1 - 1997

N2 - We used [11C]raclopride (RACLO) and positron emission tomography (PET) to study longitudinally striatal dopamine D2 receptor binding in nine patients with Parkinson's disease (PD) at an early drug-naive stage and 3-5 years later, when motor fluctuations had appeared in seven of them. Patients were treated with a combination of levodopa and dopamine agonists. Data were compared with 10 healthy controls in the same age range. Initially, patients with PD showed a significant increase of RACLO uptake in the putamen compared with controls (p <0.04). The caudate nucleus revealed values in the normal range. After 3-5 years, RACLO binding was significantly reduced in the putamen (p <0.03) and caudate nucleus (p <0.03) compared with baseline. Values were now in the control range in the putamen and reduced in the caudate nucleus (p <0.05). The clinical score at 'off' had significantly worsened (p <0.0005) compared with the first PET scan. The nine PD patients reported here had already been investigated 3-4 months after therapy began and at that time did not show a reduction of the initially increased RACLO binding capacity (data published previously). These results indicate long-term downregulation of striatal dopamine D2 receptor binding in PD. Receptor changes in the striatum of patients with PD may be induced by chronic dopaminergic therapy or occur independently of treatment, as a result of structural adaptation of the postsynaptic dopaminergic system to the progressive decline of nigrostriatal neurons.

AB - We used [11C]raclopride (RACLO) and positron emission tomography (PET) to study longitudinally striatal dopamine D2 receptor binding in nine patients with Parkinson's disease (PD) at an early drug-naive stage and 3-5 years later, when motor fluctuations had appeared in seven of them. Patients were treated with a combination of levodopa and dopamine agonists. Data were compared with 10 healthy controls in the same age range. Initially, patients with PD showed a significant increase of RACLO uptake in the putamen compared with controls (p <0.04). The caudate nucleus revealed values in the normal range. After 3-5 years, RACLO binding was significantly reduced in the putamen (p <0.03) and caudate nucleus (p <0.03) compared with baseline. Values were now in the control range in the putamen and reduced in the caudate nucleus (p <0.05). The clinical score at 'off' had significantly worsened (p <0.0005) compared with the first PET scan. The nine PD patients reported here had already been investigated 3-4 months after therapy began and at that time did not show a reduction of the initially increased RACLO binding capacity (data published previously). These results indicate long-term downregulation of striatal dopamine D2 receptor binding in PD. Receptor changes in the striatum of patients with PD may be induced by chronic dopaminergic therapy or occur independently of treatment, as a result of structural adaptation of the postsynaptic dopaminergic system to the progressive decline of nigrostriatal neurons.

KW - [C]raclopride

KW - Dopamine D receptors

KW - Parkinson's disease

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=0031031846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031031846&partnerID=8YFLogxK

U2 - 10.1002/mds.870120107

DO - 10.1002/mds.870120107

M3 - Article

C2 - 8990051

AN - SCOPUS:0031031846

VL - 12

SP - 33

EP - 38

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 1

ER -